Displaying 133 - 144 of 452
Viral Hepatitis
5

GSK: “Looking to the future of hepatitis B: how can we achieve functional cure?” - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk: "Walking the clinical care pathway for NASH: learnings from implementation" - EASL Congress 2023

View
Viral Hepatitis
5

Gilead: "Headlines In Hepatitis Delta: The Latest Advances In Care in Hepatitis Delta" - EASL Congress 2023

View
Viral Hepatitis
3

Gilead: “From Headlines To The Clinic: Expert Approaches To Patient Care in Hepatitis Delta” - EASL Congress 2023

View
General Hepatology
5

Grifols: "The burden of hepatic encephalopathy and albumin as potential approach" - EASL Congress 2023

View
Viral Hepatitis
1

GSK: "Looking To The Future Of Hepatitis B: An Expert Review Of Quantitative Hepatitis B Surface Antigen Assessment” - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Takeda: "Alpha-1 antitrypsin deficiency (AATD) - Associated liver disease: More common than you may think" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Albireo Pharma, an Ipsen Company: “New Horizons in cholestatic liver disease” - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: "Scratching beyond the surface in PBC: From current unmet medical needs to future prospects" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
6

Madrigal Pharmaceuticals: "Emerging role of the hepatic thyroid pathway in the pathophysiology of NASH" - EASL Congress 2023

View
Immune-Mediated and Cholestatic Diseases
1

Mirum Pharmaceuticals, Inc: "Meet the Experts in Cholestatic Liver Disease" - EASL Congress 2023

View
Metabolism, Alcohol & Toxicity
1

Novo Nordisk and Echosens: "Clinical challenge: Updates on the non-invasive toolbox for NASH and Fibrosis" - EASL Congress 2023

View
Displaying 133 - 144 of 452